Infliximab is a mouse/human chimeric monoclonal antibody that neutralises the activity of TNF-α, fixes complement, and leads to the death of inflammatory cells expressing TNF-α.5 Mariette X et al. noted a two to threefold high risk of lymphoma in patients receiving anti-TNF therapy such as expected in severe inflammatory diseases, and also revealed a higher risk with monoclonal-antibodies than with soluble-receptor therapy among tumour necrosis factor inhibitors (TNFi).6 The association between ankylosing spondylitis (AS) and lymphoma is not clear. Here, TNF is linked to ankylosing spondylitis.